IETH2018 8--P a disease with disturbed plateleta diseasewith func Bemiparin sodium5000IU2x1was started this risk of bleeding dueto druginterac risk of dosagefor hadbeenorganized thispa twicedaily des e adverse Decrease inplatelet values is oneoftherare sidee Discussion: 650000-700000. LMWHmedica the has beenusing thrombocytosis by adding LMWH into the treatment. We observed afavorable decrease in thrombocyte levels of the pa Conclusion: response. However, thepa sent bythemicroarray method. homozygous, Factor Vleidengene muta The pa The pa parameters suchasurea, crea Laboratory: with USG) treatment hasbeen added withthedossage 2x1,then3x1inaddi later, platelet value was 1750000,thepa Physical examina treatment. to lower extremity deepvein thrombosis (DVT) in June2008.Thepa Medical Story (anamnesis): and Research Hospital thehematology clinicsinceMay 2016. Numune Educa pa Because ofthevarious reasons, there may besomechanges amongtheLMWHsregarding the For the pa the For Case report: proximal venous thrombosis and have beenshownto furtherinhibittheinvivo thrombin genera Introduc Low molecularweightheparins have beenfound at least ase me inthelower extremity inSeptember 2013, this A FAVORABLE DECREASE INTHROMBOCYTE LEVELSCAUSED BY LMWH TREATMENT FOR ADVT ent’sclinical follow-ups. University ofHealthSciencesÜmraniye Educa Hakan Keski Use ofLMWH forthemanagementof VTEinclinicalpractice ent hadrecurrent DVT incident again inJuly2017.Factor IIG20210Agene muta ent ini c o MH o consolida ofLMWHsfor ect on: ent JAK2 V617Fposi At the the At A 53-year-old malepa PATIENT REFRACTER ESSENTIAL THROMBOCYTOSIS:A WITH case report ally received ASA 100mgandhydroxyurea 500mg3x1was alsogiven and3months on andResearch Hospital in2006.Pa ent's platelet count was decreased on: me ofdiagnosis,WBC10880,Hgb:15,9g/ Splenomegaly was con One month nadroparin calcium 3800IUtreatment was given to pa nine, AST, ALT were normal. onduring the 3 months ,pa the3months onduring ve essen ons such as 100mg ASA was also minimized. Whilethepa also was ASA such as 100mg ons Hakan Keski, MD, Hematology n uhasETaccompanying thepa ons such ent, pa on ofourtreatment and to increase inthetreatment on heterozygous mutant isdetected inthegene ent hasbeenaccepted asrefractor and anagrelide al thrombocytosis (ET)was diagnosedinHaydarpa me inthelast deepvein thrombosis a ent weight: 88kg rmed withpalpa ent. Furthermore bythisposology, thepa ects of LMWHs.In ourcase we evaluated this ects ofLMWHs.In on andResearch Hospital, ClinicofHematology ntherange of1200000-1300000. in me enoxaparin sodium 6000IUwas given as ent hasbeenfollowed in Ümraniye Educa ent’s platelet counts ranged from ec ent withcytoreduc dl Hct%46Plt:1820000,biochemical on for 2cm(168mmmeasured ve asunfrac on to thecurrent treatment. ent hadDVT for thesecond ent ,bemiparinsodium ent oned heparin in oned heparin ack.Due to Hematology and Thrombosis in Encounter International 1st ve-resistant ve-resistant ent’s ent’s ent on c tests a ent due on on.
<<